8-K: Annovis Bio Announces Unblinding of Parkinson's Phase III Data, Topline Results Expected in June After Data Cleaning Delay

Annovis Bio has completed data cleaning for its Phase III Parkinson's disease study of buntanetap, with topline efficacy data expected in June following a two-month delay.

Summary

• Annovis Bio announced the successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson's disease.
• The Phase III study was completed in the fourth quarter of 2023, with an original plan to announce data in the first quarter of 2024.
• The company experienced a delay in data cleaning due to an issue with pharmacokinetic (PK) measurements.
• Initial PK measurements showed over 50% blank samples, which was unexpected as the placebo group should have had around 33% blank samples.
• After investigation, it was found that the group evaluating the PK had modified the method, affecting the measurements.
• The PK measurements were repeated, and the expected 33% of blank samples were obtained.
• The delay in data announcement was approximately two months.
• Topline efficacy data is now expected in June.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there was a delay, the company has resolved the issue and is moving forward with data analysis. The successful completion of data cleaning is a positive step.

Positives

• The company successfully identified and corrected the issue with the pharmacokinetic measurements.
• The company is now confident in the data and ready to evaluate it for the public and the FDA.
• Topline efficacy data is expected in June.

Negatives

• The company experienced a two-month delay in announcing the data due to issues with pharmacokinetic measurements.
• Initial PK measurements showed over 50% blank samples, which was unexpected.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including patient enrollment, the effectiveness of Buntanetap, and the timing and results of clinical trials.
• There is a risk that actual results may differ materially from those implied by forward-looking statements.

Future Outlook

The company expects to announce topline efficacy data from the Phase III study of buntanetap in Parkinson's disease in June.

Management Comments

• Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, explained the reason for the delay was due to unexpected issues with pharmacokinetic measurements.
• She stated that the company promptly started searching for a possible explanation at every step of the way.
• She also stated that the company is now confident and ready to evaluate the data for the public and the FDA.

Industry Context

Annovis Bio is a clinical-stage drug platform company focused on developing therapies for neurodegenerative diseases, including Parkinson's and Alzheimer's. The successful completion of data cleaning and the upcoming topline results are important milestones in the development of buntanetap.

Comparison to Industry Standards

• The delay in data reporting due to PK measurement issues is not uncommon in clinical trials, highlighting the complexities of drug development.
• Other companies developing treatments for Parkinson's disease, such as Biogen and Roche, also face similar challenges in clinical trial execution and data analysis.
• The focus on multiple neurotoxic proteins is a unique approach compared to some competitors who target single proteins.

Stakeholder Impact

• Shareholders will be interested in the topline efficacy data expected in June.
• Patients with Parkinson's disease and their families are awaiting the results of the study.
• The FDA will be reviewing the data.

Next Steps

• The company will evaluate the data for the public and the FDA.
• The company will report topline results in June.

Key Dates

Keywords

buntanetap, Parkinson's disease, Phase III study, clinical trial, neurodegenerative diseases, data cleaning, pharmacokinetic, PK, Annovis Bio